Main Objective: To assess the dose response of the following parameters:<br>•% change in non high density lipoprotein cholesterol (non HDL C) from baseline to Week 12<br>•% change in TG from baseline to Week 12<br><br>To assess the safety and tolerability of K 877 in patients with residual cardiovascular risk despite statin controlled LDL C concentration as particularly evaluated by:<br>•Change and % change in serum creatinine from baseline to Week 12<br>•Change and % change in homocysteine from baseline to Week 12<br>;Secondary Objective: To assess the response of the following parameters:<br>•% change in HDL-C, total cholesterol (TC), and apolipoprotein (Apo) B from baseline to Wk 12<br>•% change in Apo A1 and Apo A2 from baseline to Week 12<br>•% change in LDL-C, small LDL particles (small and dense LDL), very low density lipoprotein (VLDL-C) (calculated as TC - LDL-C - HDL-C), Apo B48, Apo B100, Apo C2, Apo C3, adiponectin, fibroblast growth factor 21 (FGF21), high sensitivity C reactive protein (hsCRP), lecithin cholesterol acyltransferase (LCAT), cholesteryl ester transfer protein (CETP) mass and activity, proprotein convertase subtilisin/kexin type 9 (PCSK9) mass, HDL function (reverse cholesterol transport, HDL driven endothelial production of nitric oxide, Ion mobility analysis, HDL sub fractions (including pre beta HDL) and lipid and lipoprotein ratios  TC/HDL C, non HDL C/HDL C, Apo B/Apo A1, LDL C/Apo B, and Apo C3/Apo C2, from baseline to Wk 12<br>To measure PK parameters in a subset of patients per dose group;Primary end point(s): The primary efficacy endpoints of the study include the following:<br>• % change in non HDL C from baseline to Week 12<br>• % change in TG from baseline to Week 12<br><br>For the primary endpoints, non HDL C and TG, the primary analysis will be carried out using an analysis of covariance (ANCOVA) model with percent change from baseline to Week 12, baseline non HDL C, and baseline TG values as covariates, respectively. The superiority of K 877 groups compared to placebo will be assessed by Dunnett’s test, which will be performed separately for once daily (QD) and twice daily (BID) groups. As a secondary analysis, the dose response relationship in K 877 QD group and BID group will be separately assessed with a contrast method with the ANCOVA model. In addition, the difference between all groups will be assessed with the ANCOVA model. The primary efficacy analysis will be performed on the ITT and Per Protocol Populations.<br>The primary efficacy analysis will use the MMRM model for missing data imputation. Sensitivity analysis with LOCF method will be performed. Other possible solutions for the missing data imputation will also be explored, such as repeated measurements at Week 4, Week 8, and Week 12 with compound symmetry covariance structure and repeated measurements at Week 8 and Week 12 with compound symmetry covariance structure.<br>;Timepoint(s) of evaluation of this end point: 12 weeks